Gali Health Introduces Intelligent Personal Assistant for IBD Patients

Gali Health Introduces Intelligent Personal Assistant for IBD Patients
0
(0)

To help people with inflammatory bowel disease (IBD) manage the complex and unpredictable disorder, Gali Health has introduced an artificial intelligence (AI)-powered personal health assistant.

The free application for iOS devices, named Gali after its developer, offers access to medically vetted information, daily health monitoring, analytical tools, and emotional support. It also connects users to other patients globally.

“Our design philosophy for Gali was to create a deeply personalized experience for people with IBD,” Ilya Kupershmidt, Gali Health founder and CEO, said in a press release. “Gali understands the importance of tailored self management and works proactively with each person to provide support on the medical, lifestyle and psychological aspects of living with a chronic disease.”

The idea is to help the more than 3 million individuals in the U.S. with IBD to manage the disease between doctor appointments. The company says those living with IBD are open to mobile solutions to health concerns, but current technologies can’t fully handle these individuals’ complex and diverse health management needs.

A San Francisco-based health technology company, Gali uses cutting-edge AI technology. It seeks to continuously learn from patients and healthcare providers, who contribute their insight and experiences to Gali’s collective knowledge. While mobilizing personal health information to customize support, Gali turns the contributions into actionable collective intelligence.

“Gali Health truly empowers patients with its unique, community-centric approach to chronic disease management,” said Aydin Senkut of Felicis Ventures, a Gali Health investor. “We are excited to support the company’s vision of combining AI, health technologies and population sequencing to develop novel personalized solutions.”

Gali was designed in partnership with patient advocates as part of the Gali Health Ambassadors program. Participants provide feedback, guidance, and leadership within the Gali user community.

In the future, Gali will evolve to interact in a more human-like way, speaking many languages and supporting many more conditions, the company said in a product video accompanying the press release. It also is expected to be able to analyze genome and microbiome information to help develop personalized treatments.

The Gali mobile application may be downloaded here.

IBD is an idiopathic, dysregulated, relapsing, and debilitating immune reaction to the body’s intestinal microflora, triggered by a host of factors. The two most common forms of IBD are ulcerative colitis and Crohn’s disease.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 455
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • takeda research collaboration
  • CT-SCOUT app studied
  • gut microbes
  • Genedata

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?